Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study
Condition: Clostridium Difficile Associated Disease
MeSH terms: Clostridium Infections
Intervention: Clostridium difficile; Placebo
Intervention description: Toxoid-based Clostridium difficile vaccine; Normal saline solution (0.9% sodium chloride)
Phase: Phase 3
Study type: Interventional
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Enrollment: 1994.0
Sex: All
Minimum age: 50 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Clostridium Difficile; vaccine

Summary:

      This study will investigate a Clostridium difficile vaccine in adults 50 years of age and
      older. In half the adults, all 3 doses given are the Clostridium difficile vaccine, and in
      half the adults, 2 of the 3 doses are the Clostridium difficile vaccine with the other dose
      containing no active ingredients. The study will look at the subjects' immune response to the
      vaccine and assess the safety and tolerability of a 2-dose regimen of Clostridium difficile
      vaccine compared to a 3-dose regimen of Clostridium difficile vaccine.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Evidence of a personally signed and dated informed consent document.

          -  Willing and able to comply with study procedures.

          -  Subjects with an increased risk of future contact with healthcare systems or subjects
             who have received systemic antibiotics in the previous 12 weeks.

          -  Ability to be contacted by telephone during study participation.

        Exclusion Criteria:

          -  Pregnant female participants; breastfeeding female participants; positive urine
             pregnancy test for women of childbearing potential (WOCBP); and WOCBP who are, in the
             opinion of the investigator, sexually active and at risk for pregnancy and are
             unwilling or unable to use effective methods of contraception as outlined in this
             protocol from the signing of the informed consent until at least 28 days after the
             last dose of investigational product.

          -  Prior episode of CDI, confirmed by either laboratory test or diagnosis of
             pseudomembranous colitis at colonoscopy, at surgery, or histopathologically.

          -  Participants who may be unable to respond to vaccination due to:

               -  Metastatic malignancy; or

               -  End-stage renal disease (glomerular filtration rate <15 mL/min/1.73 m2 or on
                  dialysis).

               -  Any serious medical disorder that in the investigator's opinion is likely to be
                  fatal within the next 12 months.

               -  Congenital or acquired immunodeficiency.

          -  Known infection with human immunodeficiency virus (HIV).

          -  Any bleeding disorder or anticoagulant therapy that would contraindicate IM injection.

          -  Any contraindication to vaccination or vaccine components, including previous
             anaphylactic reaction to any vaccine or vaccine-related components.

          -  Other acute or chronic medical or psychiatric condition including recent (within the
             past year) or active suicidal ideation or behavior or laboratory abnormality that may
             increase the risk associated with study participation or investigational product
             administration or may interfere with the interpretation of study results and, in the
             judgment of the investigator, would make the participant inappropriate for entry into
             this study.

          -  Previous administration of an investigational C difficile vaccine or C difficile mAb
             therapy.

          -  Receipt of systemic corticosteroids for greater than or equal to 14 days within 28
             days before enrollment.

          -  Receipt of chronic systemic treatment with other known immunosuppressant medications,
             or radiotherapy, within 6 months before enrollment.

          -  Receipt of blood products or immunoglobulins within 6 months before enrollment.

          -  Participation in other studies involving investigational drug(s)/vaccine(s) within 28
             days prior to study entry until 1 month after the third vaccination.

          -  Investigator site staff members directly involved in the conduct of the study and
             their family members, site staff members otherwise supervised by the investigator, or
             Pfizer employees, including their family members, directly involved in the conduct of
             the study.